Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Insight into the Biosimilar Prescribing Habits of Rheumatologists

  |  Issue: July 2021  |  

The competitive pricing of biosimilars in France, Germany, Italy, Spain, the U.K. and Japan is a vital reason for the increased use of biosimilars and success in these regions. GlobalData believes a clear financial incentive is needed to increase biosimilar use in the U.S. and Australia.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Rheumatologists are prescribing more biosimilars. GaBI Online. 2021 May 31.
  2. Approval and launch dates for U.S. biosimilars—2021 GaBI Online. 2021 May 7.
  3. Lanfear D. How big pharma suppresses ‘biosimilars.’ The Wall Street Journal. 2019 Jun 23.

Related Articles

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…